News - cladribine - LARVOL VERI

15d

RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (2024-512503-39-00)

P4, N=289, Recruiting, Medizinische Hochschule Hannover | N=128 --> 289

15 days ago

Enrollment change • Minimal residual disease

Venclexta (venetoclax) • Imbruvica (ibrutinib) • cytarabine • Gazyva (obinutuzumab) • cyclophosphamide • etoposide IV • midostaurin • Vanflyta (quizartinib) • Mylotarg (gemtuzumab ozogamicin) • daunorubicin • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)

16d

Aggressive Systemic Mastocytosis Presenting as Diffuse Osteoblastic Bone Disease: A Diagnostic Pitfall Mimicking Metastatic Cancer. (PubMed, Eur J Case Rep Intern Med)

Aggressive mastocytosis can rarely present with diffuse osteoblastic bone lesions mimicking metastatic disease.Elevated serum tryptase and histopathological confirmation are essential for diagnosis, even when KIT mutations are absent.Early recognition prevents unnecessary oncologic investigations and allows timely initiation of cytoreductive therapy.

16 days ago

Journal

KIT (KIT proto-oncogene, receptor tyrosine kinase) • CD68 (CD68 Molecule)

KIT mutation

cladribine

18d

RESOLVE trial: Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease. (2024-512503-39-00)

P4, N=128, Recruiting, Medizinische Hochschule Hannover | N=52 --> 128

18 days ago

Enrollment change • Minimal residual disease

A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=24, Not yet recruiting, University of Rochester

1 month ago

New P2 trial

BCL2 (B-cell CLL/lymphoma 2)

Venclexta (venetoclax) • cytarabine • cladribine

2ms

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS) (clinicaltrials.gov)

P2, N=160, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2028 | Trial primary completion date: Feb 2026 --> Feb 2028

2 months ago

Trial completion date • Trial primary completion date

cytarabine • decitabine • cladribine • Depocyte (liposomal cytarabine)

2ms

Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia (clinicaltrials.gov)

P2, N=65, Completed, First Affiliated Hospital of Zhejiang University | Recruiting --> Completed | N=30 --> 65 | Trial primary completion date: Aug 2025 --> Apr 2025

2 months ago

Trial completion • Enrollment change • Trial primary completion date

cytarabine • cladribine • Synribo (omacetaxine mepesuccinate)

2ms

Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (clinicaltrials.gov)

P3, N=167, Terminated, Delta-Fly Pharma, Inc. | N=450 --> 167 | Trial completion date: Jun 2026 --> Jan 2026 | Recruiting --> Terminated; The data met the protocol-specified criteria for futility of the investigational treatment.

2 months ago

Enrollment change • Trial completion date • Trial termination

IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • BCL2 (B-cell CLL/lymphoma 2)

Venclexta (venetoclax) • cytarabine • azacitidine • etoposide IV • decitabine • idarubicin hydrochloride • mitoxantrone • cladribine • fludarabine IV • radgocitabine (DFP-10917)

3ms

NCI-2022-03803: A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts (clinicaltrials.gov)

P2, N=60, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

3 months ago

Trial completion date • Trial primary completion date

Venclexta (venetoclax) • cytarabine • azacitidine • cladribine • Depocyte (liposomal cytarabine)

3ms

SZBALL01: CAV Regimen for R/R Ph- B-ALL (clinicaltrials.gov)

P=N/A, N=36, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

3 months ago

Trial completion date • Trial primary completion date

Venclexta (venetoclax) • cytarabine • cladribine

3ms

SZAML02: CAV Regimen for R/R AML (clinicaltrials.gov)

P2, N=68, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

3 months ago

Trial completion date • Trial primary completion date

Venclexta (venetoclax) • cytarabine • cladribine

3ms

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (clinicaltrials.gov)

P1/2, N=80, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

3 months ago

Trial completion date • Trial primary completion date

cytarabine • Vanflyta (quizartinib) • idarubicin hydrochloride • cladribine • Starasid (cytarabine ocfosfate)

3ms

Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases. (PubMed, Ther Adv Neurol Disord)

The specific humoral and cellular response to vaccination can be compromised under alemtuzumab, azathioprine, cladribine, cyclophosphamide, CD19/CD20 antibodies (inebilizumab, ocrelizumab, ofatumumab, rituximab, ublituximab), dimethyl fumarate/diroximel fumarate, FcRn inhibitors (efgartigimod, rozanolixizumab), complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan), interleukin-6 receptor antibodies (tocilizumab, satralizumab), intravenous immunoglobulins, long-term steroid administration, methotrexate, mitoxantrone, mycophenolate mofetil, tacrolimus, teriflunomide, tumor necrosis factor-α blockers, and sphingosine-1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, siponimod), as well as after autologous stem cell transplantation...However, the humoral and cellular vaccination response may be impaired under immunotherapy necessitating close monitoring. Here, we provide applicable recommendations to optimize immunization for individuals receiving immunotherapy due to a neurological autoimmune disease.

3 months ago

Journal

IL6R (Interleukin 6 receptor)

Rituxan (rituximab) • cyclophosphamide • methotrexate • Campath (alemtuzumab) • mitoxantrone • cladribine • Arzerra (ofatumumab) • Briumvi (ublituximab-xiiy) • fingolimod • Actemra IV (tocilizumab) • Ocrevus (ocrelizumab) • Uplizna (inebilizumab-cdon)